OPRX
OptimizeRx Corp.
$7.87
-0.08
(-1.01%)
Mkt Cap
147.68M
Volume
82,175
52W Range
4.54-22.25
Sector
Healthcare
Beta
1.09
EPS (TTM)
0.24 USD
P/E Ratio
32.31
Revenue (TTM)
98.65M USD
Rev Growth (5Y)
+20.4%
EPS Growth (5Y)
N/A
Company Description
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.43M | 92.13M | 71.52M | 62.45M | 61.29M | 43.31M | 24.60M | 21.21M | 12.13M | 7.75M | 7.22M | 6.50M |
| Net Income | 5.13M | (20.11M) | (17.57M) | (11.44M) | 378,079 | (2.21M) | (3.14M) | 226,344 | (2.10M) | (1.54M) | (595,140) | (1.03M) |
| EPS | 0.28 | -1.10 | -1.03 | -0.64 | 0.02 | -0.15 | -0.23 | 0.02 | -0.21 | -0.16 | -0.07 | -0.14 |
| Free Cash Flow | 18.66M | 4.78M | (8.11M) | 10.41M | 240,040 | (6.44M) | (3.25M) | 701,542 | (1.52M) | (815,503) | 414,146 | (466,302) |
| FCF / Share | 1.01 | 0.26 | -0.47 | 0.59 | 0.01 | -0.43 | -0.24 | 0.06 | -0.16 | -0.08 | 0.05 | -0.06 |
| Operating CF | 18.71M | 4.89M | (7.24M) | 10.65M | 726,039 | (6.31M) | (1.66M) | 792,555 | (1.48M) | (465,965) | 515,110 | (56,350) |
| Total Assets | 176.92M | 171.17M | 183.37M | 134.65M | 140.99M | 60.33M | 56.64M | 25.05M | 9.76M | 11.48M | 12.31M | 7.03M |
| Total Debt | 26.10M | 33.19M | 36.82M | 234,434 | 327,708 | 448,753 | 564,184 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 23.36M | 13.38M | 13.85M | 18.21M | 84.68M | 10.52M | 18.85M | 8.91M | 5.12M | 7.03M | 8.21M | 3.45M |
| Book Value | 128.29M | 117.00M | 126.55M | 126.11M | 131.38M | 49.97M | 44.86M | 18.46M | 6.22M | 7.81M | 8.94M | 4.61M |
| Return on Equity | 0.04 | -0.17 | -0.14 | -0.09 | 0.00 | -0.04 | -0.07 | 0.01 | -0.34 | -0.20 | -0.07 | -0.22 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.50M | 19.84M | 32.24M | 26.07M | 29.20M | 21.93M | 32.32M | 21.31M | 18.81M | 19.69M | 28.37M | 16.33M |
| Net Income | (703,000) | (495,000) | 5.02M | 779,000 | 1.53M | (2.20M) | (78,000) | (9.12M) | (4.01M) | (6.90M) | (4.14M) | (2.87M) |
| EPS | -0.04 | -0.03 | 0.27 | 0.04 | 0.08 | -0.12 | -0.00 | -0.50 | -0.22 | -0.38 | -0.23 | -0.17 |
| Free Cash Flow | 8.58M | (488,000) | 7.08M | 3.19M | 4.55M | 3.84M | 78,000 | 1.70M | 697,000 | 1.97M | (6.26M) | 1.15M |
| FCF / Share | 0.46 | -0.03 | 0.38 | 0.17 | 0.25 | 0.21 | 0.00 | 0.09 | 0.04 | 0.11 | -0.35 | 0.07 |
| Operating CF | 8.61M | (467,000) | 7.09M | 3.20M | 4.56M | 3.86M | 198,000 | 1.79M | 782,000 | 2.12M | (6.26M) | 1.47M |
| Total Assets | 164.32M | 167.26M | 176.92M | 170.32M | 169.26M | 167.77M | 171.17M | 165.20M | 172.88M | 176.37M | 183.37M | 123.93M |
| Total Debt | 19.48M | 23.72M | 26.10M | 28.61M | 28.98M | 32.80M | 33.19M | 35.72M | 36.09M | 36.46M | 36.82M | 148,642 |
| Cash & Equiv | 24.10M | 20.17M | 23.36M | 19.52M | 16.59M | 16.57M | 13.38M | 16.13M | 14.96M | 15.18M | 13.85M | 9.92M |
| Book Value | 131.08M | 129.61M | 128.29M | 122.26M | 119.28M | 116.27M | 117.00M | 114.47M | 121.02M | 122.54M | 126.55M | 116.11M |
| Return on Equity | -0.01 | -0.00 | 0.04 | 0.01 | 0.01 | -0.02 | -0.00 | -0.08 | -0.03 | -0.06 | -0.03 | -0.02 |
OPRX News
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
AWM Investment Company Inc. Invests $1.38 Million in OptimizeRx Corp. $OPRX
Dimensional Fund Advisors LP Purchases 102,661 Shares of OptimizeRx Corp. $OPRX
OptimizeRx Q2 Earnings Call Highlights
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer